# Clinical Trials Data BRAF - Document 10

# Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

## Clinical Trial: https://clinicaltrials.gov/study/NCT01124669

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Diagnosis of refractory non-small cell lung cancer\n\* Received sorafenib tosylate on protocol ECOG-E2501\n\* Available blood specimens\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Samples submitted for research from patients enrolled on E2501",

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
This trial description \*\*does not mention BRAF status\*\* as either an inclusion or exclusion criterion. Therefore, based on the information provided, it's \*\*impossible to determine\*\* if a patient with a BRAF mutation would be eligible. The crucial criteria are having refractory non-small cell lung cancer, prior treatment with sorafenib tosylate on the specific ECOG-E2501 protocol, and available blood specimens.